Loading...
PHN logo

Pharmanutra S.p.A.BIT:PHN Stock Report

Market Cap €889.5m
Share Price
€92.90
€94.33
1.5% undervalued intrinsic discount
1Y84.3%
7D4.7%
1D
Portfolio Value
​
View

Pharmanutra S.p.A.

BIT:PHN Stock Report

Market Cap: €889.5m

Pharmanutra (PHN) Stock Overview

A nutraceutical company, engages in the research and development and marketing of food supplements and medical devices in Europe, the Middle East, Far East, North America, South America, and internationally. More details

PHN fundamental analysis
Snowflake Score
Valuation0/6
Future Growth4/6
Past Performance6/6
Financial Health5/6
Dividends2/6

Rewards

Earnings are forecast to grow 19.78% per year

Earnings grew by 28.1% over the past year

Risk Analysis

No risks detected for PHN from our risk checks.

PHN Community Fair Values

Create Narrative

See what 12 others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Pharmanutra S.p.A. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Pharmanutra
Historical stock prices
Current Share Price€92.90
52 Week High€94.45
52 Week Low€38.75
Beta0.13
1 Month Change19.72%
3 Month Change32.53%
1 Year Change84.33%
3 Year Change53.81%
5 Year Change99.78%
Change since IPO564.05%

Recent News & Updates

Recent updates

Analysis Article • Nov 29

Why Investors Shouldn't Be Surprised By Pharmanutra S.p.A.'s (BIT:PHN) 26% Share Price Surge

Pharmanutra S.p.A. ( BIT:PHN ) shares have had a really impressive month, gaining 26% after a shaky period beforehand...
Analysis Article • Nov 27

Here's Why Pharmanutra (BIT:PHN) Can Manage Its Debt Responsibly

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analysis Article • Mar 20

Pharmanutra's (BIT:PHN) Dividend Will Be Increased To €1.00

Pharmanutra S.p.A.'s ( BIT:PHN ) dividend will be increasing from last year's payment of the same period to €1.00 on...
Analysis Article • Sep 11

Investors Interested In Pharmanutra S.p.A.'s (BIT:PHN) Earnings

Pharmanutra S.p.A.'s ( BIT:PHN ) price-to-earnings (or "P/E") ratio of 52.9x might make it look like a strong sell...
Analysis Article • Mar 23

Pharmanutra's (BIT:PHN) Shareholders Have More To Worry About Than Only Soft Earnings

Pharmanutra S.p.A.'s ( BIT:PHN ) recent weak earnings report didn't cause a big stock movement. Our analysis suggests...
Analysis Article • Sep 26

Is Now The Time To Put Pharmanutra (BIT:PHN) On Your Watchlist?

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...
Analysis Article • May 16

These 4 Measures Indicate That Pharmanutra (BIT:PHN) Is Using Debt Safely

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Analysis Article • Jan 11

Pharmanutra (BIT:PHN) Could Easily Take On More Debt

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Analysis Article • Nov 02

Capital Allocation Trends At Pharmanutra (BIT:PHN) Aren't Ideal

What trends should we look for it we want to identify stocks that can multiply in value over the long term? One common...
Analysis Article • Aug 03

Pharmanutra (BIT:PHN) Will Be Hoping To Turn Its Returns On Capital Around

What are the early trends we should look for to identify a stock that could multiply in value over the long term...
Analysis Article • May 20

Is Now The Time To Put Pharmanutra (BIT:PHN) On Your Watchlist?

It's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks...
Analysis Article • Apr 19

Returns On Capital Signal Tricky Times Ahead For Pharmanutra (BIT:PHN)

To find a multi-bagger stock, what are the underlying trends we should look for in a business? Typically, we'll want to...
Analysis Article • Mar 10

Are Strong Financial Prospects The Force That Is Driving The Momentum In Pharmanutra S.p.A.'s BIT:PHN) Stock?

Pharmanutra (BIT:PHN) has had a great run on the share market with its stock up by a significant 12% over the last...
Analysis Article • Feb 17

Is There More To The Story Than Pharmanutra's (BIT:PHN) Earnings Growth?

Statistically speaking, it is less risky to invest in profitable companies than in unprofitable ones. Having said that...
Analysis Article • Feb 01

Should You Be Adding Pharmanutra (BIT:PHN) To Your Watchlist Today?

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Analysis Article • Jan 18

Is Pharmanutra S.p.A. (BIT:PHN) A Smart Choice For Dividend Investors?

Could Pharmanutra S.p.A. ( BIT:PHN ) be an attractive dividend share to own for the long haul? Investors are often...
Analysis Article • Jan 04

Is Pharmanutra (BIT:PHN) A Risky Investment?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Analysis Article • Dec 22

Shareholders Of Pharmanutra (BIT:PHN) Must Be Happy With Their 220% Total Return

The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But when you pick a company...
Analysis Article • Dec 08

Do Insiders Own Lots Of Shares In Pharmanutra S.p.A. (BIT:PHN)?

Every investor in Pharmanutra S.p.A. ( BIT:PHN ) should be aware of the most powerful shareholder groups. Institutions...
Analysis Article • Nov 23

Is Pharmanutra S.p.A.'s(BIT:PHN) Recent Stock Performance Tethered To Its Strong Fundamentals?

Pharmanutra's (BIT:PHN) stock is up by a considerable 20% over the past three months. Given that the market rewards...

Shareholder Returns

PHNIT Personal ProductsIT Market
7D4.7%0.4%0.6%
1Y84.3%-9.9%19.1%

Return vs Industry: PHN exceeded the Italian Personal Products industry which returned -10.3% over the past year.

Return vs Market: PHN exceeded the Italian Market which returned 18.1% over the past year.

Price Volatility

Is PHN's price volatile compared to industry and market?
PHN volatility
PHN Average Weekly Movement5.9%
Personal Products Industry Average Movement5.1%
Market Average Movement5.1%
10% most volatile stocks in IT Market8.6%
10% least volatile stocks in IT Market3.1%

Stable Share Price: PHN has not had significant price volatility in the past 3 months compared to the Italian market.

Volatility Over Time: PHN's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2000128n/awww.pharmanutra.it

Pharmanutra S.p.A., a nutraceutical company, engages in the research and development and marketing of food supplements and medical devices in Europe, the Middle East, Far East, North America, South America, and internationally. The company produces and distributes raw materials and active ingredients for the food, pharmaceutical, and dietary supplement industries. It offers Sucrosomial, a delivery system that optimises nutrient transport and absorption for minimising gastrointestinal side effects; and Cetylated Fatty Acids, a formulation for muscle and joint recovery in physiotherapy and sports.

Pharmanutra S.p.A. Fundamentals Summary

How do Pharmanutra's earnings and revenue compare to its market cap?
PHN fundamental statistics
Market cap€889.53m
Earnings (TTM)€21.02m
Revenue (TTM)€138.73m
42.3x
P/E Ratio
6.4x
P/S Ratio

Is PHN overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PHN income statement (TTM)
Revenue€138.73m
Cost of Revenue€67.97m
Gross Profit€70.76m
Other Expenses€49.74m
Earnings€21.02m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)2.20
Gross Margin51.01%
Net Profit Margin15.15%
Debt/Equity Ratio25.6%

How did PHN perform over the long term?

See historical performance and comparison

Dividends

1.3%
Current Dividend Yield
58%
Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/08 10:08
End of Day Share Price 2026/06/08 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Pharmanutra S.p.A. is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Anna FrontaniBerenberg
Andrea RandoneIntermonte SIM S.p.A.
Giorgio TavoliniIntermonte SIM S.p.A.